Aggredyne closes $3 million Series A convertible preferred stock financing Aggredyne.

.. Aggredyne closes $3 million Series A convertible preferred stock financing Aggredyne, Inc., a Houston-based biomedical diagnostics organization that is defining a fresh regular for platelet function screening, sold out and closed a $3 million Series A convertible recommended stock financing. Aggredyne is also getting ready to file with the meals and Drug Administration a 510 for clearance to advertise its initial product, the AggreGuideTM A-100, and related blood platelet screening.These mice are engineered to develop plaques similar to those within the brains of patients with Alzheimer’s. Positive results from these research would encourage further investigation of MSDC-0160 in the treating Alzheimer’s. Related StoriesGenovate begins building of Insulin Ecological Industrial Recreation area in Changzhou National Hi-tech DistrictHigher insulin levels linked to even worse prognosis in advanced breasts cancerNovo Nordisk announces FDA approval of Tresiba for diabetes treatmentInitial findings were presented at the 10th Annual International Conference on Alzheimer’s Drug Discovery ( in Jersey Town, N.J.